Base de dados : MEDLINE
Pesquisa : G08.686.605.154 [Categoria DeCS]
Referências encontradas : 55 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 6 ir para página                

  1 / 55 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27462657
[Au] Autor:Moreano B
[Ti] Título:[App and web are unreliable].
[Ti] Título:Auf App und Web ist kaum Verlass..
[So] Source:MMW Fortschr Med;158(12):3, 2016 Jun 23.
[Is] ISSN:1438-3276
[Cp] País de publicação:Germany
[La] Idioma:ger
[Mh] Termos MeSH primário: Período Fértil
Internet
Aplicativos Móveis
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:NEWS
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160726
[Lr] Data última revisão:
160726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160728
[St] Status:MEDLINE


  2 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27390383
[Au] Autor:Duane M; Contreras A; Jensen ET; White A
[Ad] Endereço:From the Fertility Appreciation Collaborative to Teach the Science (FACTS), Dayton, OH (MD, AC); the Department of Family Medicine, Georgetown University, Washington, DC (MD); the Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC (ETJ); and the Department o
[Ti] Título:The Performance of Fertility Awareness-based Method Apps Marketed to Avoid Pregnancy.
[So] Source:J Am Board Fam Med;29(4):508-11, 2016 Jul-Aug.
[Is] ISSN:1558-7118
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: In recent years there has been an explosion in the development of medical apps, with more than 40,000 apps now available. Nearly 100 apps allow women to track their fertility and menstrual cycles and can be used to avoid or achieve pregnancy. Apps offer a convenient way to track fertility biomarkers. However, only some use evidence-based fertility awareness-based methods (FABMs), which with ideal use have rates of effectiveness similar to those of commonly used forms of hormonal birth control. Since having a baby or preventing a pregnancy are important responsibilities, it is critical that women and couples have access to reliable, evidence-based apps that allow them to accurately track their fertility. METHODS: We developed a tool to evaluate and rate fertility apps. This tool is specifically designed to help couples avoid pregnancy. RESULTS: Results showed that the majority of fertility apps are not based on evidence-based FABMs or include a disclaimer discouraging use for avoiding pregnancy. However, at least 1 app in each FABM category (except symptohormonal methods) had a perfect score on accuracy. CONCLUSION: Relying solely on an app to use an FABM, without appropriate training in the method, may not be sufficient to prevent pregnancy.
[Mh] Termos MeSH primário: Anticoncepção/métodos
Serviços de Planejamento Familiar/métodos
Período Fértil/fisiologia
Aplicações da Informática Médica
Métodos Naturais de Planejamento Familiar/métodos
[Mh] Termos MeSH secundário: Biomarcadores
Medicina Baseada em Evidências/métodos
Feminino
Seres Humanos
Guias de Prática Clínica como Assunto
Gravidez
[Pt] Tipo de publicação:COMPARATIVE STUDY; EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160709
[St] Status:MEDLINE
[do] DOI:10.3122/jabfm.2016.04.160022


  3 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27275788
[Au] Autor:Setton R; Tierney C; Tsai T
[Ad] Endereço:Departments of Obstetrics and Gynecology, Weill Cornell Medical College, New York, and New York-Presbyterian/Queens, Queens, New York.
[Ti] Título:The Accuracy of Web Sites and Cellular Phone Applications in Predicting the Fertile Window.
[So] Source:Obstet Gynecol;128(1):58-63, 2016 Jul.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the validity of fertility web sites and applications (apps) by comparing the predicted fertile window of these modalities to the actual fertile window of a standard 28-day cycle. METHODS: This was a descriptive study. The top resulting free web sites and electronic apps downloadable to a cellular phone that provide calendars for fertility and ovulation prediction were assessed. Cycles were standardized to 28 days in length, 4 days of menses, and the last menstrual period was set to January 1, 2015. The predicted date of ovulation and fertility window generated were compared with an actual estimated date of ovulation on cycle day 15, January 15, and a fertile window consisting of cycle day 10 to cycle day 15, the day of ovulation plus the preceding 5 cycle days, January 10-15. RESULTS: Data from 20 web sites and 33 apps were collected. Of all the web sites and apps used, one web site and three apps predicted the precise fertile window. CONCLUSION: Web sites and electronic apps used by the general public to predict fertile windows are generally inaccurate, although the clinical effect of this inaccuracy is unknown. Although they all include the most fertile cycle day, the range of the fertility window varies widely. Patients who are trying to conceive with the assistance of calendars generated from web sites and electronic apps should be counseled on the inaccuracy of these modalities.
[Mh] Termos MeSH primário: Telefone Celular
Período Fértil
Internet
Aplicativos Móveis/normas
Métodos Naturais de Planejamento Familiar
[Mh] Termos MeSH secundário: Adulto
Acurácia dos Dados
Feminino
Fertilidade/fisiologia
Seres Humanos
Métodos Naturais de Planejamento Familiar/métodos
Métodos Naturais de Planejamento Familiar/normas
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160609
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000001341


  4 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:26892070
[Au] Autor:Veltman-Verhulst SM; Hughes E; Ayeleke RO; Cohlen BJ
[Ad] Endereço:University Medical Center Utrecht, Department of Reproductive Medicine and Gynecology, Room F5.126, PO Box 85500,, Utrecht, Netherlands, 3508 GA.
[Ti] Título:Intra-uterine insemination for unexplained subfertility.
[So] Source:Cochrane Database Syst Rev;2:CD001838, 2016 Feb 19.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Intra-uterine insemination (IUI) is a widely used fertility treatment for couples with unexplained subfertility. Although IUI is less invasive and less expensive thAppendixan in vitro fertilisation (IVF), the safety of IUI in combination with ovarian hyperstimulation (OH) is debated. The main concern about IUI treatment with OH is the increase in multiple pregnancy rate. This is an update of a Cochrane review (Veltman-Verhulst 2012) originally published in 2006 and updated in 2012. OBJECTIVES: To determine whether, for couples with unexplained subfertility, IUI improves the live birth rate compared with timed intercourse (TI), or expectant management, both with and without ovarian hyperstimulation (OH). SEARCH METHODS: We searched the Cochrane Gynaecology and Fertility (formerly Cochrane Menstrual Disorders and Subfertility Group) Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, inception to Issue 11, 2015), Ovid MEDLINE, Ovid EMBASE, PsycINFO and trial registers, all from inception to December 2015 and reference lists of articles. Authors of identified studies were contacted for missing or unpublished data. The evidence is current to December 2015. SELECTION CRITERIA: Truly randomised controlled trial (RCT) comparisons of IUI versus TI, in natural or stimulated cycles. Only couples with unexplained subfertility were included. DATA COLLECTION AND ANALYSIS: Two review authors independently performed study selection, quality assessment and data extraction. We extracted outcomes, and pooled data and, where possible, we carried out subgroup and sensitivity analyses. MAIN RESULTS: We included 14 trials including 1867 women. IUI versus TI or expectant management both in natural cycleLive birth rate (all cycles)There was no evidence of a difference in cumulative live births between the two groups (Odds Ratio (OR) 1.60, 95% confidence interval (CI) 0.92 to 2.78; 1 RCT; n = 334; moderate quality evidence). The evidence suggested that if the chance of a live birth in TI was assumed to be 16%, that of IUI would be between 15% and 34%.Multiple pregnancy rateThere was no evidence of a difference in multiple pregnancy rate between the two treatment groups (OR 0.50, 95% CI 0.04 to 5.53; 1 RCT; n = 334; moderate quality evidence). IUI versus TI or expectant management both in stimulated cycleLive birth rate (all cycles)There was no evidence of a difference between the two treatment groups (OR 1.59, 95% CI 0.88 to 2.88; 2 RCTs; n = 208; I(2) = 72%; moderate quality evidence). The evidence suggested that if the chance of achieving a live birth in TI was assumed to be 26%, the chance of a live birth with IUI would be between 23% and 50%.Multiple pregnancy rateThere was no evidence of a difference in multiple pregnancy rates between the two treatment groups (OR 1.46, 95% CI 0.55 to 3.87; 4 RCTs, n = 316; I(2) = 0%; low quality evidence). IUI in a natural cycle versus IUI in a stimulated cycle Live birth rate (all cycles)An increase in live birth rate was found for women who were treated with IUI in a stimulated cycle compared with those who underwent IUI in natural cycle (OR 0.48, 95% CI 0.29 to 0.82; 4 RCTs, n = 396; I(2) = 0%; moderate quality evidence). The evidence suggested that if the chance of a live birth in IUI in a stimulated cycle was assumed to be 25%, the chance of a live birth in IUI in a natural cycle would be between 9% and 21%.Multiple pregnancy rateThere was no evidence of a difference in multiple pregnancy rate between the two treatment groups (OR 0.33, 95% CI 0.01 to 8.70; 2 RCTs; n = 65; low quality evidence). IUI in a stimulated cycle versus TI or expectant management in a natural cycleLive birth rate (all cycles)There was no evidence of a difference in live birth rate between the two treatment groups (OR 0.82, 95% CI 0.45 to 1.49; 1 RCT; n = 253; moderate quality evidence). The evidence suggested that if the chance of a live birth in TI or expectant management in a natural cycle was assumed to be 24%, the chance of a live birth in IUI in a stimulated cycle would be between 12% and 32%.Multiple pregnancy rateThere was no evidence of a difference in multiple pregnancy rate between the two treatment groups (OR 2.00, 95% CI 0.18 to 22.34; 2 RCTs; n = 304; moderate quality evidence). IUI in natural cycle versus TI or expectant management in stimulated cycle Live birth rate (all cycles)There was evidence of an increase in live births for IUI (OR 1.95, 95% CI 1.10 to 3.44; 1 RCT, n = 342; moderate quality evidence). The evidence suggested that if the chance of a live birth in TI in a stimulated cycle was assumed to be 13%, the chance of a live birth in IUI in a natural cycle would be between 14% and 34%.Multiple pregnancy rateThere was no evidence of a difference in multiple pregnancy rate between the groups (OR 1.05, 95% CI 0.07 to 16.90; 1 RCT; n = 342; moderate quality evidence).The quality of the evidence was assessed using GRADE methods. Quality ranged from low to moderate, the main limitation being imprecision in the findings for both live birth and multiple pregnancy.. AUTHORS' CONCLUSIONS: This systematic review did not find conclusive evidence of a difference in live birth or multiple pregnancy in most of the comparisons for couples with unexplained subfertility treated with intra-uterine insemination (IUI) when compared with timed intercourse (TI), both with and without ovarian hyperstimulation (OH). There were insufficient studies to allow for pooling of data on the important outcome measures for each of the comparisons.
[Mh] Termos MeSH primário: Infertilidade/terapia
Inseminação Artificial/métodos
Indução da Ovulação/métodos
Taxa de Gravidez
[Mh] Termos MeSH secundário: Coito
Feminino
Período Fértil/fisiologia
Seres Humanos
Inseminação Artificial/efeitos adversos
Nascimento Vivo/epidemiologia
Masculino
Indução da Ovulação/efeitos adversos
Gravidez
Gravidez Múltipla
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Em] Mês de entrada:1606
[Cu] Atualização por classe:160301
[Lr] Data última revisão:
160301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160220
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD001838.pub5


  5 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26074135
[Au] Autor:Song SH; Kim DS; Yoon TK; Hong JY; Shim SH
[Ad] Endereço:Department of Urology, Fertility Center, CHA Gangnam Medical Center, Seoul, Korea.
[Ti] Título:Sexual function and stress level of male partners of infertile couples during the fertile period.
[So] Source:BJU Int;117(1):173-6, 2016 Jan.
[Is] ISSN:1464-410X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To evaluate the sexual function and stress level during timed intercourse (TI) of male partners of infertile couples. PATIENTS AND METHODS: The study included 236 male partners of couples with >1 year of infertility who sought medical care or an evaluation of couple infertility. Besides infertility evaluation, all men were asked to complete the five-item version of the International Index of Erectile Function (IIEF-5) for evaluation of sexual function, and stresses related to infertility and TI were measured using 10-division visual analogue scales (VAS). RESULTS: Stress levels for sexual function were higher during fertile than non-fertile periods in109 of the 236 (46.2%) male partners, with 122 (51.7%) reporting no difference in stress during fertile and non-fertile periods. The mean (sd) VAS score of sexual relationship stress was significantly higher during fertile than non-fertile periods, at 3.4 (2.6) vs 2.1 (2.2) (P < 0.001). Of the 236 men, 21 (8.9%) reported more than mild-to-moderate erectile dysfunction (ED; IIEF-5 score ≤16) and 99 (42%) reported mild ED (IIEF-5 score 17-21). CONCLUSION: Male partners of infertile couples experience significantly higher TI-related stresses during the fertile period compared with the non-fertile period. Sexual dysfunction is also common in male partners of infertile couples. Medical personnel dealing with infertile couples should be aware of these potential problems in male partners and provide appropriate counselling.
[Mh] Termos MeSH primário: Período Fértil/psicologia
Infertilidade/psicologia
Parceiros Sexuais/psicologia
Estresse Psicológico/epidemiologia
Estresse Psicológico/psicologia
[Mh] Termos MeSH secundário: Adulto
Disfunção Erétil/psicologia
Seres Humanos
Masculino
Inquéritos e Questionários
Escala Visual Analógica
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1604
[Cu] Atualização por classe:151217
[Lr] Data última revisão:
151217
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150616
[St] Status:MEDLINE
[do] DOI:10.1111/bju.13201


  6 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26050642
[Au] Autor:Wijayagunawardane MP; Hambruch N; Haeger JD; Pfarrer C
[Ad] Endereço:Department of Anatomy, University of Veterinary Medicine Hannover, 30173 Hannover, Germany.
[Ti] Título:Effect of epidermal growth factor (EGF) on the phosphorylation of mitogen-activated protein kinase (MAPK) in the bovine oviduct in vitro: Alteration by heat stress.
[So] Source:J Reprod Dev;61(5):383-9, 2015.
[Is] ISSN:1348-4400
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Epidermal growth factor (EGF) has been shown to be involved in control of the oviductal microenvironment. To elucidate the potential mechanisms responsible for the detrimental effect of heat stress and to identify the relation with the endocrine status, the effects of EGF on the level of phosphorylated mitogen-activated-protein kinase (MAPK) and proliferation of bovine oviductal epithelial cells (OECs) exposed to different cyclic ovarian steroidal environments (luteal phase (LP), follicular phase (FP) and postovulatory phase (PO)) and temperatures (mild heat stress (40 C) and severe heat stress (43 C)) were investigated. Western blot was performed to evaluate phosphorylated MAPK, while proliferation was analyzed by MTT assay. Stimulation of OECs with EGF alone or with EGF in the PO and FP environments significantly increased the amount of phosphorylated MAPK, with MAPK 44 phosphorylation being highest during exposure to PO conditions. These effects were not observed in the LP. Heat treatment completely blocked effects of EGF on phosphorylated MAPK. Additionally, severe heat stress led to a significantly lower basal level of phosphorylated MAPK. PD98059 (MAPK inhibitor) completely abolished EGF-stimulated MAPK phosphorylation and OECs proliferation. Overall the results indicate that EGF has the potential to increase the amount of phosphorylated MAPK in OECs and therefore could be involved in regulation of the bovine oviductal microenvironment. However, these regulatory mechanisms may be compromised in the presence of heat stress (high ambient temperature), leading to low fertility rates and impaired embryo survival.
[Mh] Termos MeSH primário: Fator de Crescimento Epidérmico/metabolismo
Sistema de Sinalização das MAP Quinases
Proteínas Quinases Ativadas por Mitógeno/metabolismo
Oviductos/metabolismo
Processamento de Proteína Pós-Traducional
Receptor do Fator de Crescimento Epidérmico/agonistas
Regulação para Cima
[Mh] Termos MeSH secundário: Animais
Bovinos
Proliferação Celular/efeitos dos fármacos
Células Cultivadas
Fator de Crescimento Epidérmico/genética
Feminino
Período Fértil/efeitos dos fármacos
Período Fértil/metabolismo
Fase Folicular/efeitos dos fármacos
Fase Folicular/metabolismo
Temperatura Alta/efeitos adversos
Seres Humanos
Fase Luteal/efeitos dos fármacos
Fase Luteal/metabolismo
Sistema de Sinalização das MAP Quinases/efeitos dos fármacos
Proteínas Quinases Ativadas por Mitógeno/antagonistas & inibidores
Membrana Mucosa/citologia
Membrana Mucosa/efeitos dos fármacos
Membrana Mucosa/metabolismo
Oviductos/citologia
Oviductos/efeitos dos fármacos
Fosforilação/efeitos dos fármacos
Inibidores de Proteínas Quinases/farmacologia
Processamento de Proteína Pós-Traducional/efeitos dos fármacos
Receptor do Fator de Crescimento Epidérmico/metabolismo
Proteínas Recombinantes/metabolismo
Regulação para Cima/efeitos dos fármacos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Protein Kinase Inhibitors); 0 (Recombinant Proteins); 62229-50-9 (Epidermal Growth Factor); EC 2.7.10.1 (Receptor, Epidermal Growth Factor); EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150609
[St] Status:MEDLINE
[do] DOI:10.1262/jrd.2014-061


  7 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25979615
[Au] Autor:Mabileau G; Schwarzinger M; Flores J; Patrat C; Luton D; Epelboin S; Mandelbrot L; Matheron S; Yazdanpanah Y
[Ad] Endereço:Institut National de la Santé et de la Recherche Médicale (INSERM), Infection Antimicrobials Modelling & Evolution (IAME), unity 1137, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France. Electronic address: guillaume.mabileau@inserm.fr.
[Ti] Título:HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
[So] Source:Am J Obstet Gynecol;213(3):341.e1-12, 2015 Sep.
[Is] ISSN:1097-6868
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: We sought to assess the residual risk of HIV transmission, cost, and cost-effectiveness of various strategies that can help fertile HIV-uninfected female/HIV-1-infected male on combination antiretroviral therapy with plasma HIV RNA <50 copies/mL couples to have a child: (1) unprotected sexual intercourse (treatment as prevention); (2) treatment as prevention limited to fertile days (targeting fertile days); (3) treatment as prevention with preexposure prophylaxis (tenofovir/emtricitabine); (4) treatment as prevention and preexposure prophylaxis limited to fertile days; or (5) medically assisted procreation (MAP). STUDY DESIGN: This was a model-based, cost-effectiveness analysis performed from a French societal perspective. Input parameters derived from international literature included: 85% probability of live births in different strategies, 0.0083%/mo HIV transmission risk with unprotected vaginal intercourse, 1% HIV mother-to-child transmission rate, and 4.4% birth defect risk related to combination antiretroviral therapy when the mother is infected at conception. Targeting fertile days and preexposure prophylaxis were estimated to decrease the risk of HIV transmission by 80% and 67%, respectively, and by 93.4% for preexposure prophylaxis limited to fertile days (the relative risk of transmission considering the combination of both strategies assuming to be (1-80%)*(1-67%) = 16.6% in basecase). Tenofovir/emtricitabine monthly cost was set at €540. RESULTS: The HIV transmission risk was highest with treatment as prevention and lowest for MAP (5.4 and 0.0 HIV-infected women/10,000 pregnancies, respectively). Targeting fertile days was more effective than preexposure prophylaxis (0.9 vs 1.8) and associated with lowest costs. Preexposure prophylaxis limited to fertile days was more effective than targeting fertile days (0.3 vs 0.9) with a cost-effectiveness ratio of €1,130,000/life year saved; MAP cost-effectiveness ratio when compared with preexposure prophylaxis limited to fertile days was €3,600,000/life year saved. Results were robust to multiple sensitivity analyses. CONCLUSION: Targeting fertile days is associated with a low risk of HIV transmission in fertile HIV-uninfected female/male with controlled HIV-1 infection couples. The risk is lower with preexposure prophylaxis limited to fertile days, or MAP, but these strategies are associated with unfavorable cost-effectiveness ratios under their current costs.
[Mh] Termos MeSH primário: Fármacos Anti-HIV/uso terapêutico
Período Fértil
Infecções por HIV/prevenção & controle
Custos de Cuidados de Saúde
Transmissão Vertical de Doença Infecciosa/prevenção & controle
Profilaxia Pré-Exposição/economia
Técnicas de Reprodução Assistida/economia
[Mh] Termos MeSH secundário: Adenina/análogos & derivados
Adenina/economia
Adenina/uso terapêutico
Fármacos Anti-HIV/economia
Análise Custo-Benefício
Desoxicitidina/análogos & derivados
Desoxicitidina/economia
Desoxicitidina/uso terapêutico
Emtricitabina
Feminino
França
Infecções por HIV/economia
Infecções por HIV/transmissão
Seres Humanos
Transmissão Vertical de Doença Infecciosa/economia
Inseminação Artificial
Masculino
Modelos Econômicos
Organofosfonatos/economia
Organofosfonatos/uso terapêutico
Gravidez
Sêmen/virologia
Tenofovir
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (Organophosphonates); 0W860991D6 (Deoxycytidine); 99YXE507IL (Tenofovir); G70B4ETF4S (Emtricitabine); JAC85A2161 (Adenine)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:150517
[St] Status:MEDLINE


  8 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25785599
[Au] Autor:Teixeira AL; Ramos PS; Vianna LC; Ricardo DR
[Ad] Endereço:Maternity Hospital Therezinha de Jesus, Faculty of Medical and Health Sciences-SUPREMA, Juiz de Fora, MG, Brazil; Postgraduate Program in Exercise and Sports Sciences, State University of Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil.
[Ti] Título:Effects of ovarian hormones and oral contraceptive pills on cardiac vagal withdrawal at the onset of dynamic exercise.
[So] Source:PLoS One;10(3):e0119626, 2015.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to investigate the effects of the ovarian hormones and the use of oral contraceptive pills (OCP) on cardiac vagal withdrawal at the onset of dynamic exercise. Thirty physically active women aged 19-32 years were divided into two groups: OCP users (n = 17) and non-OCP users (n = 13). Participants were studied randomly at three different phases of the menstrual cycle: early follicular (day 3.6 ± 1.2; range 1-5), ovulatory (day 14.3 ± 0.8; range 13-16) and midluteal (day 21.3 ± 0.8; range 20-24), according to endogenous (in non-OCP users) or exogenous (in OCP users) estradiol and progesterone variations. The cardiac vagal withdrawal was represented by the cardiac vagal index (CVI), which was obtained by the 4-s exercise test. Additionally, resting heart rate, systolic (SBP) and diastolic blood pressure (DBP) were obtained. The CVI was not significantly different between the three phases of the menstrual cycle in either the non-OCP users (early follicular: 1.58 ± 0.1; ovulatory: 1.56 ± 0.1; midluteal: 1.58 ± 0.1, P > 0.05) or OCP users (early follicular: 1.47 ± 0.1; ovulatory: 1.49 ± 0.1; midluteal: 1.47 ± 0.1, P > 0.05) (mean ± SEM). Resting cardiovascular responses were not affected by hormonal phase or OCP use, except that the SBP was higher in the OCP users than non-OCP users in all phases of the cycle (P < 0.05). In summary, our results demonstrate that cardiac vagal withdrawal at the onset of dynamic exercise was not impacted by the menstrual cycle or OCP use in physically active women.
[Mh] Termos MeSH primário: Anticoncepcionais Orais/farmacologia
Exercício
Coração/efeitos dos fármacos
Nervo Vago/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Pressão Sanguínea/efeitos dos fármacos
Anticoncepção
Estradiol/sangue
Estradiol/farmacologia
Feminino
Período Fértil/efeitos dos fármacos
Período Fértil/fisiologia
Fase Folicular/efeitos dos fármacos
Fase Folicular/fisiologia
Coração/inervação
Frequência Cardíaca/efeitos dos fármacos
Seres Humanos
Fase Luteal/efeitos dos fármacos
Fase Luteal/fisiologia
Progesterona/sangue
Progesterona/farmacologia
Descanso
Nervo Vago/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Contraceptives, Oral); 4G7DS2Q64Y (Progesterone); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:150325
[Lr] Data última revisão:
150325
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150319
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0119626


  9 / 55 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25772771
[Au] Autor:Stanford JB
[Ad] Endereço:Departments of Family and Preventive Medicine and Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah.
[Ti] Título:Revisiting the fertile window.
[So] Source:Fertil Steril;103(5):1152-3, 2015 May.
[Is] ISSN:1556-5653
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Período Fértil
Fertilidade
Ovário/fisiologia
Detecção da Ovulação/métodos
Ovulação
Autocuidado
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
[Pt] Tipo de publicação:COMMENT; JOURNAL ARTICLE
[Em] Mês de entrada:1507
[Cu] Atualização por classe:150502
[Lr] Data última revisão:
150502
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150317
[St] Status:MEDLINE


  10 / 55 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25724738
[Au] Autor:Ecochard R; Duterque O; Leiva R; Bouchard T; Vigil P
[Ad] Endereço:Service de Biostatistique, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon 1, Villeurbanne, France; Equipe Biostatistique-Santé, Laboratoire de Biométrie et Biologie Evolutive, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5558, Ville
[Ti] Título:Self-identification of the clinical fertile window and the ovulation period.
[So] Source:Fertil Steril;103(5):1319-25.e3, 2015 May.
[Is] ISSN:1556-5653
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To assess the sensitivity and specificity of the self-identified fertile window. DESIGN: Observational study. SETTING: Not applicable. PATIENT(S): A total of 107 women. INTERVENTION(S): Women recorded cervical mucus observation and basal body temperature daily while undergoing daily ovarian ultrasound. MAIN OUTCOME MEASURE(S): The biological fertile window, defined as the 6 days up to and including the day of ovulation; and the 2-day ovulation window, defined as the day before and the day of ovulation. RESULT(S): The self-identification of the biological fertile window by the observation of any type of cervical mucus provides 100% sensitivity but poor specificity, yielding a clinical fertile window of 11 days. However, the identification of the biological fertile window by peak mucus (defined as clear, slippery, or stretchy mucus related to estrogen) yielded 96% sensitivity and improved specificity. The appearance of the peak mucus preceded the biological fertile window in less than 10% of the cycles. Likewise, this type of mucus identified the ovulation window with 88% sensitivity. CONCLUSION(S): These results suggest that, when perceived accurately, more accurate clinical self-detection of the fertile window can be obtained by identification of peak mucus. This may improve efforts to focus intercourse in the fertile phase for couples with fertility concerns.
[Mh] Termos MeSH primário: Período Fértil
Fertilidade
Ovário/fisiologia
Detecção da Ovulação/métodos
Ovulação
Autocuidado
[Mh] Termos MeSH secundário: Regulação da Temperatura Corporal
Muco do Colo Uterino/secreção
Europa (Continente)
Feminino
Seres Humanos
Ovário/diagnóstico por imagem
Valor Preditivo dos Testes
Fatores de Tempo
Ultrassonografia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1507
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150301
[St] Status:MEDLINE



página 1 de 6 ir para página                
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde